KR101314880B1 - 관절류머티즘 치료제 - Google Patents

관절류머티즘 치료제 Download PDF

Info

Publication number
KR101314880B1
KR101314880B1 KR1020117024354A KR20117024354A KR101314880B1 KR 101314880 B1 KR101314880 B1 KR 101314880B1 KR 1020117024354 A KR1020117024354 A KR 1020117024354A KR 20117024354 A KR20117024354 A KR 20117024354A KR 101314880 B1 KR101314880 B1 KR 101314880B1
Authority
KR
South Korea
Prior art keywords
amino acid
acid sequence
seq
set forth
sequence set
Prior art date
Application number
KR1020117024354A
Other languages
English (en)
Korean (ko)
Other versions
KR20110139734A (ko
Inventor
도모유키 이가와
신야 이시이
아츠히코 마에다
미카 사쿠라이
데츠오 고지마
다츠히코 다치바나
히로타케 시라이와
히로유키 츠노다
요시노부 히구치
Original Assignee
추가이 세이야쿠 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 추가이 세이야쿠 가부시키가이샤 filed Critical 추가이 세이야쿠 가부시키가이샤
Publication of KR20110139734A publication Critical patent/KR20110139734A/ko
Application granted granted Critical
Publication of KR101314880B1 publication Critical patent/KR101314880B1/ko

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
KR1020117024354A 2009-03-19 2010-03-19 관절류머티즘 치료제 KR101314880B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JPJP-P-2009-067358 2009-03-19
JP2009067358 2009-03-19
PCT/JP2010/054763 WO2010107108A1 (ja) 2009-03-19 2010-03-19 関節リウマチ治療剤

Publications (2)

Publication Number Publication Date
KR20110139734A KR20110139734A (ko) 2011-12-29
KR101314880B1 true KR101314880B1 (ko) 2013-10-04

Family

ID=42739764

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020117024354A KR101314880B1 (ko) 2009-03-19 2010-03-19 관절류머티즘 치료제

Country Status (5)

Country Link
JP (2) JP4809930B2 (ro)
KR (1) KR101314880B1 (ro)
RU (1) RU2524152C2 (ro)
TW (1) TWI457134B (ro)
WO (1) WO2010107108A1 (ro)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CL2008000188A1 (es) 2007-01-23 2008-07-18 Chugai Pharmaceutical Co Ltd Agente para suprimir la reaccion de rechazo cronica que comprende como ingrediente activo un inhibidor de il-6; y uso del inhibidor de il-6.
CA2728243C (en) 2008-06-05 2020-03-10 National Cancer Center Il-6 inhibitor for suppressing neuroinvasion in pancreatic cancer
TWI440469B (zh) 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
DK2578231T3 (da) 2010-05-28 2022-12-12 Chugai Pharmaceutical Co Ltd Antitumor-t-celle-reaktionsforstærker
US10782290B2 (en) 2013-06-11 2020-09-22 National Center Of Neurology And Psychiatry Method for predicting post-therapy prognosis of relapsing-remitting multiple sclerosis (RRMS) patient, and method for determining applicability of novel therapy
TW202339800A (zh) 2015-02-27 2023-10-16 日商中外製藥股份有限公司 Il-6受體抗體用於製備醫藥組成物的用途
ES2888801T3 (es) 2015-05-19 2022-01-07 Nat Center Neurology & Psychiatry Método para determinar la aplicación de una terapia nueva en pacientes con esclerosis múltiple (EM)
JP7185884B2 (ja) 2017-05-02 2022-12-08 国立研究開発法人国立精神・神経医療研究センター Ｉｌ－６及び好中球の関連する疾患の治療効果の予測及び判定方法
US11692037B2 (en) 2017-10-20 2023-07-04 Hyogo College Of Medicine Anti-IL-6 receptor antibody-containing medicinal composition for preventing post-surgical adhesion
TWI822728B (zh) 2018-01-31 2023-11-21 加藤元一 含有il-6抑制劑的哮喘治療劑
BR112021017702A2 (pt) 2019-03-29 2021-11-16 Chugai Pharmaceutical Co Ltd Inibidor contendo anticorpo anti-receptor de il-6 para inibição de deterioração da função bhe
TW202110477A (zh) 2019-04-17 2021-03-16 國立大學法人廣島大學 以組合投予il-6 抑制劑與ccr2 抑制劑為特徵之泌尿器官癌的治療劑
AU2022232856A1 (en) 2021-03-12 2023-10-26 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition for treatment or prevention of myasthenia gravis

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008020079A1 (en) 2006-08-18 2008-02-21 Ablynx N.V. Amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of deseases and disorders associated with il-6-mediated signalling

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ298325B6 (cs) * 1994-10-21 2007-08-29 Kishimoto@Tadamitsu Farmaceutický prípravek pro prevenci nebo lécení plasmocytosy
DK2476705T3 (en) * 2004-12-28 2015-12-14 Innate Pharma Monoclonal antibodies against NKG2A
WO2009010539A2 (en) * 2007-07-19 2009-01-22 Ablynx. N.V. Receptor for interleukin-6 (il-6) from macaca fascicularis
CA2700498C (en) * 2007-09-26 2016-01-05 Chugai Seiyaku Kabushiki Kaisha Anti-il-6 receptor antibody
MY180713A (en) * 2007-09-26 2020-12-07 Chugai Pharmaceutical Co Ltd Modified antibody constant region
PL2708558T3 (pl) * 2008-04-11 2018-09-28 Chugai Seiyaku Kabushiki Kaisha Cząsteczka wiążąca antygen zdolna do wiązania dwóch lub więcej cząsteczek antygenu w sposób powtarzalny
TWI440469B (zh) * 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008020079A1 (en) 2006-08-18 2008-02-21 Ablynx N.V. Amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of deseases and disorders associated with il-6-mediated signalling

Also Published As

Publication number Publication date
RU2524152C2 (ru) 2014-07-27
JPWO2010107108A1 (ja) 2012-09-20
JP4809930B2 (ja) 2011-11-09
JP2011219478A (ja) 2011-11-04
TWI457134B (zh) 2014-10-21
RU2011142183A (ru) 2013-04-27
TW201034685A (en) 2010-10-01
KR20110139734A (ko) 2011-12-29
WO2010107108A1 (ja) 2010-09-23

Similar Documents

Publication Publication Date Title
KR101314880B1 (ko) 관절류머티즘 치료제
JP6952454B2 (ja) 抗腫瘍ｔ細胞応答増強剤
CA2648644C (en) Muscle regeneration promoter
US20180222986A1 (en) Cancer metastasis inhibitor
RU2490025C2 (ru) Терапевтические средства, используемые против реакции трансплантат против хозяина, содержащие в качестве активного ингредиента ингибитор рецептора интерлейкина-6
TWI528973B (zh) Nerve infiltration inhibitor
CA2595786C (en) Compositions and methods for treating fibrotic disorders
EP1210425B1 (en) Baff receptor (bcma), an immunoregulatory agent
RU2450830C2 (ru) Средства для лечения кардиопатии
KR100877033B1 (ko) 패혈증의 치료 또는 예방을 위한 ｉｌ-18 저해물질의 용도
JP4744763B2 (ja) Ｉｌ−１８阻害剤の用途
BRPI0609762A2 (pt) uso de um agente que reduza o nìvel de il-21 e/ou il-21r, e, método para identificar um composto para tratar, melhorar ou prevenir a fibrose ou um distúrbio associado com a fibrose em um indivìduo
US9394362B2 (en) IL-21 antibodies and methods of making or using the antibodies
JP2010095445A (ja) Ｉｌ−６アンタゴニストを有効成分とする炎症性筋疾患治療剤
AU2004209967A1 (en) Methods for modulating an inflammatory response
Wippel-Slupetzky et al. Future perspectives in the treatment of psoriasis
Georgiev et al. Pharmacological properties of monoclonal antibodies directed against interleukins
JP2005516907A (ja) 霊長類ｉｆｎ−ガンマ結合分子の使用
Simant et al. Interleukin-6, a major player of cytokine storm in COVID-19 and its alleviation by therapeutic antibodies
Yao et al. Sonelokimab. Interleukin-17A and-F nanobody, Treatment of moderate to severe psoriasis, Treatment of hidradenitis suppurativa
Gonzalez-Gonzalez et al. Secukinumab
JP2021073245A (ja) Ｉｌ−６阻害剤を有効成分とする精神疾患治療剤

Legal Events

Date Code Title Description
A201 Request for examination
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20160919

Year of fee payment: 4